Media Newsroom of

Biosceptre

Jonas Webb Building Babaraham Research Centre Babaraham
Cambridge, Cambridgeshire - CB22 SAT England
Phone: +44 1223 496 090
Website: http://www.biosceptre.com
Biosceptre

Biosceptre International is a public, unlisted biotechnology company based in Cambridge, UK. Biosceptre is developing and commercializing antibody technologies to address a wide range of applications in the treatment of cancer. P2X7 is a major cellular receptor with a significant role in apoptosis. Our technology is based on the fundamental discovery of a conformationally distinct variant of P2X7 that is highly specific to cancer cells but not on normal cells, and broadly occurring across a range of cancers. Biosceptre has developed and patented a number of immune oncological therapeutics that are in and entering the clinic and that bind to nfP2X7 (the "non-functional" form of P2X7) on cancer cells, but not to normal P2X7, offering the potential for significant advancement in the treatment of a broad range of cancers.

Biosceptre Joins European COST Group focussed on Ion Channels

Biosceptre Joins European COST Group focussed on Ion Channels

Biosceptre announces today its membership of the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406. This project, established in 2014, created the Ion channel-Immune response network that brings together internationally recognised scientists and companies across 15…

Professor Paul de Souza joins Biosceptre executive team as Chief Medical Officer

Professor Paul de Souza joins Biosceptre executive team as Chief Medical Officer

Biosceptre is pleased to announce that Professor Paul de Souza has accepted the role of Chief Medical Officer at the company. Initially, Dr de Souza will provide guidance and insight on the Phase I clinical trial for Biosceptre's cancer vaccine…

Biosceptre's Phase 1 Clinical Trial for anti-cancer antibody BIL03s approved by Ethics Committee

Biosceptre's proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal antibody therapy) was granted conditional approval by the Bellberry Ethics committee. Biosceptre is now seeking partners and external funding to progress BIL03s into the clinic.Biosceptre has high confidence in the…

Biosceptre publishes a clinical study of topical drug BIL010t as therapy for BCC

Basal cell carcinoma (BCC) is the most common type of cancer, and its incidence is increasing. Biosceptre has discovered a variant of an important signalling protein P2X7, termed nfP2X7, that occurs in the cancer cell membrane and is present in…

Appointment of Sir Gregory Winter as Interim Chair of Biosceptre's Board of Directors

Biosceptre is pleased to announce the appointment of Sir Gregory Winter as Chair of the Biosceptre Board of Directors. Sir Gregory has led the Scientific Advisory Board of Biosceptre for over 4 years and joined the Board of Directors as…

Professor Francesco Di Virgilio joins Biosceptre Scientific Advisory Board

Biosceptre, the therapeutic antibody and immunotherapy company targeting the non-functional form of the P2X7 receptor (nfP2X7) across a broad range of cancers, announced today that Professor Francesco Di Virgilio, an expert in the role of P2X7 in cancer based at…

Sir Gregory Winter joins Biosceptre Board

Biosceptre, the therapeutic antibody company targeting the nfP2X7 receptor across a broad range of cancers, announced today that Sir Gregory Winter has taken a board position as non-executive Director. Sir Gregory has been strongly associated with Biosceptre since 2011 as…

Biosceptre Wins SMART Award Grant

Biosceptre, a biopharmaceutical company developing innovative diagnostic and therapeutic approaches to cancer, today announced that the UK government-backed Innovate UK SMART award scheme has awarded the company £100,000 to support pre-clinical development of diagnostic approaches and antibodies to target Kidney…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login